12,372 trials
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1 — 18.0; 16.5; 3.7; 3.0 Percentage of participants
Apathy · Alzheimer's Disease
Primary: Neuropsychiatric Inventory (NPI) — -4.5; -3.1 score on a scale
Non-Small Cell Lung Cancer
Primary: Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1 — 121; 77.5; 78.3 micrograms per milliliter (μg/mL)
Amyotrophic Lateral Sclerosis
Primary: Disease Progression as Assessed by the ALSFRS-R-Slope — -1.02; -1.05 ALSFRS-R total score points per month
HER2-Positive Breast Carcinoma · Hormone Receptor-Positive Breast Carcinoma · Stage IB Breast Cancer AJCC v7
Primary: Percent of Patients With Pathological Complete Response (pCR) in the Breast and Post Therapy Lymph Nodes — 41.2; 45.8 percentage of participants
Preneoplastic Conditions · Prostatic Intraepithelial Neoplasia
Primary: Efficacy of Toremifene in the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN) — 54.9; 59.5 % of participants cancer-free…
Healthy
Primary: Insulin Secretion Rate During Exendin-9,39 Infusion vs. Insulin Secretion Rate During Saline Infusion — 191; 171 nmol/min per 300 min — p=0.02
Niemann-Pick Disease, Type C
Primary: Change From Baseline in the Niemann-Pick Disease Type C (NPC) Disease Severity Assessed Based on the 5-domain NPCCSS Total Scores — 0.76; 2.15 score on a scale — p=0.0456
Waldenström's Macroglobulinemia
Primary: Percentage of Participants Achieving Either a Complete Response (CR) or Very Good Partial Response (VGPR) Using an Adaptation of the Response Criteria Updated at the…
Open-Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Time-Matched Intraocular Pressure (IOP) for Bimatoprost SR Treated Eyes — -3.7; -4.0; -2.5; -3.2 Millimeters of Mercury (mmHg)
Sinusitis · Respiratory Tract Infections
Primary: The Mean Pediatric Rhinosinusitis Symptom Scale (PRSS) Score Over the First 10 Days of Follow-up According to the Presence of Pathogens in the Nasopharynx at Enrollment…
Head and Neck Neoplasms
Primary: Event-free Survival (EFS) — NA; 46.6 Months — p=0.0429
Homozygous Familial Hypercholesterolemia
Primary: Part A: Maximum Observed Serum Concentration (Cmax) of Evinacumab — 238 Milligrams per Liter (mg/L)
Localized Osteosarcoma · Metastatic Osteosarcoma
Primary: Event-free Survival (EFS) — 74; 77; 55; 53 Percentage EFS — p=0.214
Clostridium Difficile Infection
Primary: Area Under the Concentration-Time Curve of Bezlotoxumab From Time 0 to Infinity (AUC0-inf) — 56100; 43200 hr*ug/mL